The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gene signature to predict hypophysitis in patients with melanoma treated with anti-PD-1 in adjuvant setting.
 
Ester Simeone
No Relationships to Disclose
 
Domenico Mallardo
No Relationships to Disclose
 
Lucia Festino
No Relationships to Disclose
 
Vito Vanella
No Relationships to Disclose
 
Claudia Trojaniello
No Relationships to Disclose
 
Maria Grazia Vitale
No Relationships to Disclose
 
Margaret Ottaviano
Honoraria - Novartis
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis/Pfizer; Pierre Fabre; Sun Pharma
 
Francesca Sparano
No Relationships to Disclose
 
Bianca Arianna Facchini
No Relationships to Disclose
 
Eleonora Cioli
No Relationships to Disclose
 
Antonio Isaja
No Relationships to Disclose
 
Corrado Caraco
No Relationships to Disclose
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; Anaveon; AstraZeneca; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Erasca, Inc; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; MSD Oncology; Pfizer; Pierre Fabre; Replimune